Nuance Investments Lowered Its Patterson Companies (PDCO) Holding; Illumina (ILMN) Shorts Increased By 2.58%

January 23, 2018 - By Marguerite Chambers

Nuance Investments Llc decreased Patterson Companies Inc (PDCO) stake by 64.29% reported in 2017Q3 SEC filing. Nuance Investments Llc sold 412,570 shares as Patterson Companies Inc (PDCO)’s stock declined 2.93%. The Nuance Investments Llc holds 229,209 shares with $8.86M value, down from 641,779 last quarter. Patterson Companies Inc now has $3.42 billion valuation. The stock decreased 0.30% or $0.11 during the last trading session, reaching $36.91. About 61,322 shares traded. Patterson Companies, Inc. (NASDAQ:PDCO) has declined 4.97% since January 23, 2017 and is downtrending. It has underperformed by 21.67% the S&P500.

Illumina Incorporated (NASDAQ:ILMN) had an increase of 2.58% in short interest. ILMN’s SI was 2.91 million shares in January as released by FINRA. Its up 2.58% from 2.83 million shares previously. With 806,100 avg volume, 4 days are for Illumina Incorporated (NASDAQ:ILMN)’s short sellers to cover ILMN’s short positions. The SI to Illumina Incorporated’s float is 2%. The stock decreased 1.04% or $2.55 during the last trading session, reaching $242.64. About 172,439 shares traded. Illumina, Inc. (NASDAQ:ILMN) has risen 28.24% since January 23, 2017 and is uptrending. It has outperformed by 11.54% the S&P500.

Among 28 analysts covering Illumina Inc (NASDAQ:ILMN), 17 have Buy rating, 1 Sell and 10 Hold. Therefore 61% are positive. Illumina Inc had 87 analyst reports since July 22, 2015 according to SRatingsIntel. On Wednesday, August 26 the stock rating was initiated by Cantor Fitzgerald with “Buy”. The company was downgraded on Tuesday, October 11 by CItigroup. The firm has “Overweight” rating given on Wednesday, October 21 by Piper Jaffray. Morgan Stanley maintained Illumina, Inc. (NASDAQ:ILMN) rating on Tuesday, May 3. Morgan Stanley has “Equal-Weight” rating and $130 target. The company was upgraded on Wednesday, August 26 by Citigroup. The firm has “Hold” rating given on Tuesday, October 11 by Canaccord Genuity. The firm has “Neutral” rating by Citigroup given on Tuesday, October 11. The rating was downgraded by Wells Fargo on Thursday, January 7 to “Market Perform”. Canaccord Genuity maintained it with “Buy” rating and $250 target in Wednesday, July 22 report. Cowen & Co maintained the stock with “Buy” rating in Wednesday, October 25 report.

Investors sentiment decreased to 1.1 in 2017 Q3. Its down 0.24, from 1.34 in 2017Q2. It fall, as 33 investors sold Illumina, Inc. shares while 167 reduced holdings. 55 funds opened positions while 165 raised stakes. 131.54 million shares or 1.36% less from 133.36 million shares in 2017Q2 were reported. 15,650 were accumulated by De Burlo Grp Inc. Cypress Asset Mgmt Tx reported 0.07% in Illumina, Inc. (NASDAQ:ILMN). Nordea Inv Mgmt invested in 0% or 7,076 shares. Clarivest Asset Mngmt Ltd Llc owns 0% invested in Illumina, Inc. (NASDAQ:ILMN) for 6 shares. Telemus Cap Limited Liability reported 1,471 shares. Private Asset holds 0.35% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 2,158 shares. Symphony Asset Mgmt Ltd Liability Corp holds 0.51% or 23,100 shares in its portfolio. Jackson Square Ptnrs Limited Liability has 284,986 shares for 0.28% of their portfolio. Barclays Public Llc has 0.03% invested in Illumina, Inc. (NASDAQ:ILMN) for 151,655 shares. Amalgamated Commercial Bank stated it has 17,564 shares or 0.11% of all its holdings. Robeco Institutional Asset Bv accumulated 0% or 2,242 shares. Advantus Capital Inc holds 0.08% of its portfolio in Illumina, Inc. (NASDAQ:ILMN) for 14,911 shares. Pnc Fincl Svcs Gru invested in 0.01% or 60,706 shares. Perigon Wealth Mngmt Lc stated it has 4,377 shares. Piedmont Invest Advisors reported 0.01% stake.

Illumina, Inc. provides sequencing and array solutions for genetic analysis. The company has market cap of $35.43 billion. The companyÂ’s sequencing by synthesis technology provides researchers with various applications and the ability to sequence mammalian genomes. It has a 46.23 P/E ratio. It also offers arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow for the detection of known genetic markers on a single array.

Since August 1, 2017, it had 0 insider purchases, and 25 insider sales for $51.16 million activity. Shares for $4.47M were sold by FLATLEY JAY T. Ronaghi Mostafa sold $4.20 million worth of stock or 20,000 shares. Dadswell Charles sold $29,828 worth of stock. Shares for $413,759 were sold by Stapley Marc. Bouchard Michel sold $610,440 worth of stock or 3,131 shares. Van Oene Mark sold $259,013 worth of stock. Another trade for 10,800 shares valued at $2.11M was made by EASTHAM KARIN on Wednesday, August 2.

Among 14 analysts covering Patterson Companies Inc. (NASDAQ:PDCO), 2 have Buy rating, 2 Sell and 10 Hold. Therefore 14% are positive. Patterson Companies Inc. had 33 analyst reports since August 28, 2015 according to SRatingsIntel. UBS initiated the shares of PDCO in report on Thursday, October 6 with “Neutral” rating. Robert W. Baird maintained Patterson Companies, Inc. (NASDAQ:PDCO) rating on Friday, August 26. Robert W. Baird has “Neutral” rating and $49 target. The firm earned “Hold” rating on Friday, May 27 by Evercore. As per Friday, December 8, the company rating was initiated by Deutsche Bank. The rating was maintained by William Blair on Friday, August 28 with “Market Perform”. UBS upgraded the stock to “Hold” rating in Friday, August 25 report. The company was maintained on Tuesday, January 2 by Robert W. Baird. The firm earned “Underweight” rating on Wednesday, December 6 by Morgan Stanley. The stock has “Outperform” rating by Robert W. Baird on Tuesday, January 3. The company was maintained on Wednesday, August 9 by Stifel Nicolaus.

Analysts await Patterson Companies, Inc. (NASDAQ:PDCO) to report earnings on February, 22. They expect $0.52 EPS, down 10.34% or $0.06 from last year’s $0.58 per share. PDCO’s profit will be $48.17M for 17.75 P/E if the $0.52 EPS becomes a reality. After $0.51 actual EPS reported by Patterson Companies, Inc. for the previous quarter, Wall Street now forecasts 1.96% EPS growth.

Investors sentiment increased to 1.25 in 2017 Q3. Its up 0.46, from 0.79 in 2017Q2. It increased, as 39 investors sold PDCO shares while 102 reduced holdings. 46 funds opened positions while 130 raised stakes. 88.39 million shares or 5.32% more from 83.93 million shares in 2017Q2 were reported. Jefferies Group Inc Ltd Liability Company reported 6,700 shares stake. Jane Street Grp Incorporated Limited Liability Company invested 0% of its portfolio in Patterson Companies, Inc. (NASDAQ:PDCO). Connecticut-based Aqr Ltd Liability Corporation has invested 0% in Patterson Companies, Inc. (NASDAQ:PDCO). Toth Fin Advisory reported 87,028 shares stake. The New York-based Amalgamated Bank has invested 0.02% in Patterson Companies, Inc. (NASDAQ:PDCO). Bluemountain Mgmt Ltd Llc reported 21,750 shares. Advantus Mgmt reported 7,998 shares stake. Lombard Odier Asset Management (Usa) Corporation stated it has 0.15% in Patterson Companies, Inc. (NASDAQ:PDCO). Rand Wealth Ltd Liability Com holds 8,760 shares or 0.04% of its portfolio. Van Eck Assoc stated it has 880,341 shares or 0.17% of all its holdings. Dorsey & Whitney Ltd Liability stated it has 72,258 shares or 0.56% of all its holdings. Fenimore Asset Mngmt Inc accumulated 996,970 shares. 1.45M were reported by Millennium Mngmt. Shell Asset Mngmt stated it has 0.18% of its portfolio in Patterson Companies, Inc. (NASDAQ:PDCO). Employees Retirement Association Of Colorado has invested 0% of its portfolio in Patterson Companies, Inc. (NASDAQ:PDCO).

Since October 11, 2017, it had 0 buys, and 2 sales for $54,833 activity. On Wednesday, October 11 GUGINO ANN B sold $27,548 worth of Patterson Companies, Inc. (NASDAQ:PDCO) or 750 shares.